Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06333392

Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial

Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:

1. SSLs will be more visible as they "float" on the submucosa and contract into the lumen, while full distension by gas stretches the mucosa, making detection of flat lesions more difficult. 2. Water works like a magnifying lens, making detection and detailed characterisation of lesions easier. 3. uEMR is eased. 4. Improved bowel cleansing

The goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2) insufflation and TUC during withdrawal in patients participating in colonoscopy in the Norwegian and Swedish colorectal cancer screening programme after a positive fecal immunochemical test.

The overarching research questions of the present trial is whether colonoscopy outcomes are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the new technique reduces the ecological footprint of the colonoscopy examination.

The project has five main hypotheses:

1. TUC is superior to the standard approach (CO2 withdrawal) regarding detection of proximal SSLs. 2. TUC increases the rate of complete resection of lesions >= 10mm. 3. TUC reduces the rate of painful colonoscopies and vasovagal reactions. 4. TUC reduces the health care costs by reduced use of single use accessories and reduced number of redundant colonoscopies to obtain polypfree colon. 5. TUC reduces the carbon footprint by reduced use of single use accessories.

If TUC is superior to gas insufflation, the technique may be implemented rapidly since the technique is easy to learn. This study will increase endoscopy competence at participating centres. The centres are involved in national colonoscopy training programs, so the technique will quickly be passed on to other hospitals and screening centres.

The trial can be linked to three of the Global Goals:

* Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor). * Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening. * Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All individuals referred to colonoscopy after a positive FIT screening at the participating screening centres

Exclusion criteria

  • Individuals with a CRC diagnosis within the last 10 years.

Treatment and study plan

Total underwater colonoscopy

Procedure

one grooup will be randomized to receive a total underwater colonoscopy

Conventional colonoscopy

Procedure

one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal

Primary outcomes

  1. Proximal sessile serrated lesion detection rate

    Time frame: when histopathology report is clear, about 4 weeks after colonoscopy

    The proportion of colonoscopies where at least one proximal SSL is detected

Secondary outcomes

  1. Complete resection rate for lesions > 10mm

    Time frame: 4 weeks after colonoscopy

    see above

  2. Rate of painful procedures and vasovagal reactions

    Time frame: during and immediately after colonoscopy

    se above

  3. Leakage after colonoscopy

    Time frame: Questionnaire 1-7 days after colonoscopy

    water leakage on the way home after colonoscopy

  4. Detection rate for other neoplasia than SSL

    Time frame: about 4 weeks after colonoscopy

    see above

  5. Withdrawal time

    Time frame: immediately after colonoscopy

    see above

  6. Total procedure time

    Time frame: immediately after colonoscopy

    see above

  7. Bowel cleansing quality

    Time frame: immediately after colonoscopy

    with help of BBPS

  8. Complications

    Time frame: within 30 days after colonoscopy

    Significant bleedings and perforations

  9. Number of colonoscopies to achieve polyp free colon

    Time frame: after last colonoscopy per patient

    see above

  10. Single use accessories for the procedure

    Time frame: immediately after colonoscopy

    number of single use accesoires per colonoscopy

  11. Willingness to repeat colonoscopy

    Time frame: questionnaire 1-2 weeks after colonoscopy

    Willingness to repeat colonoscopy the same way if new colonoscopy is necessary

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Lisa Schult, MD, PhD

CONTACT

[email protected]

+47 67 80 94 00

Thomas de Lange, MD, associate prof

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Vestre Viken Hospital Trust

Other

Collaborators

  • Ostfold Hospital Trust
  • Sahlgrenska University Hospital
  • Ullevaal University Hospital
  • University Hospital, Akershus

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Mar 27, 2024
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.